AN2 Therapeutics Inc - Asset Resilience Ratio
AN2 Therapeutics Inc (ANTX) has an Asset Resilience Ratio of 61.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how AN2 Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of AN2 Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down AN2 Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ANTX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $38.06 Million | 61.44% |
| Total Liquid Assets | $38.06 Million | 61.44% |
Asset Resilience Insights
- Very High Liquidity: AN2 Therapeutics Inc maintains exceptional liquid asset reserves at 61.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AN2 Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare AN2 Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for AN2 Therapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for AN2 Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.44% | $38.06 Million | $61.95 Million | -6.18pp |
| 2024-12-31 | 67.62% | $62.27 Million | $92.09 Million | +1.56pp |
| 2023-12-31 | 66.06% | $91.65 Million | $138.74 Million | -1.07pp |
| 2022-12-31 | 67.12% | $68.84 Million | $102.56 Million | -4.01pp |
| 2021-12-31 | 71.13% | $46.46 Million | $65.32 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $4.23 Million | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more